Originally published as JCO Early Release 10.1200/JCO.2005.02.568 on May 2 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kienle, D. L. Articles by Stilgenbauer, S. Search for Related Content PubMed PubMed Citation Articles by Kienle, D. L. Articles by Stilgenbauer, S. Social Bookmarking                            What's this?

Evidence for Distinct Pathomechanisms in Genetic Subgroups of Chronic Lymphocytic Leukemia Revealed by Quantitative Expression Analysis of Cell Cycle, Activation, and Apoptosis-Associated Genes

From the Department of Internal Medicine III, University of Ulm, Ulm; Department of Molecular Genetics and Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany; Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria

Address reprint requests to Stephan Stilgenbauer, Internal Medicine III, University of Ulm, Robert-Koch-Straße 8, 89081 Ulm, Germany; e-mail: stephan.stilgenbauer{at}medizin.uni-ulm.de

PURPOSE: In patients with chronic lymphocytic leukemia (CLL), the VH mutation status and genomic aberrations (13q–, +12q, 11q–, 17p–) identify distinct prognostic subgroups. The aim was to elucidate biologic mechanisms through which these genetic markers may exert their pathogenic influence.

PATIENTS AND METHODS: Twenty-four genes involved in apoptosis, cell cycle, B-cell activation, and B-cell receptor (BCR) signaling were analyzed by real-time quantitative reverse transcription polymerase chain reaction (RQ-PCR) in 82 CLL cases constituting prototypic genetic CLL subgroups as defined by the VH mutation status and the genomic aberrations 13q–, +12, 11q–, and 17p–.

RESULTS: The VH mutation subgroups were characterized by a differential expression of the BCR associated genes ZAP70 and PI3K. Among the subgroups defined by genomic aberrations, there was a deregulation of candidate genes from the affected critical genomic regions such as CDK4 (up), ATM (down), and TP53 (down) in the groups +12, 11q–, and 17p–, respectively. Additionally, the genomic subgroups were characterized by a significant deregulation of cell cycle and apoptosis regulators: AKT (up) in 13q, E2F1 (up) in +12, MYC (up) and BCL-2 (down) in 17p–, and CCND3 (down) in 11q– as well as 17p–. The 17p– subgroup showed an additional down-regulation of BCR-associated genes such as SYK and PI3K.

CONCLUSION: The characteristic gene expression patterns observed implicate a differential regulation of cell cycle, apoptosis, and BCR signaling in the genetic subgroups illustrating distinct pathomechanisms and are evidence for a gene dosage effect being operative in CLL. These findings link the biologic diversity and clinical heterogeneity of CLL.

Supported by the DFG (Sti 296/1-1), Deutsche Krebshilfe (70-3183-Li1), Wilhelm Sander Stiftung (2002.095.1), Jubiläumsfonds of the Austrian National Bank (No. 9964; U.J.).

Presented at the Annual Meeting of the American Society of Hematology, San Diego, CA, 2003.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Herling, K. A. Patel, N. Weit, N. Lilienthal, M. Hallek, M. J. Keating, and D. Jones High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia Blood, November 19, 2009; 114(21): 4675 - 4686. [Abstract] [Full Text] [PDF]

				M. Buchner, S. Fuchs, G. Prinz, D. Pfeifer, K. Bartholome, M. Burger, N. Chevalier, L. Vallat, J. Timmer, J. G. Gribben, et al. Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia Cancer Res., July 1, 2009; 69(13): 5424 - 5432. [Abstract] [Full Text] [PDF]

				L. Tracey, M. Aggarwal, M. Garcia-Cosio, R. Villuendas, P. Algara, M. Sanchez-Beato, A. Sanchez-Aguilera, J. F. Garcia, A. Rodriguez, F. I. Camacho, et al. Somatic hypermutation signature in B-cell low-grade lymphomas Haematologica, August 1, 2008; 93(8): 1186 - 1194. [Abstract] [Full Text] [PDF]

				T. Zenz, S. Habe, A. Benner, D. Kienle, H. Dohner, and S. Stilgenbauer The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia Haematologica, July 1, 2008; 93(7): 1111 - 1113. [Full Text] [PDF]

				G. Roos, R. Rosenquist, and S. Stilgenbauer Response: Or both? Blood, June 15, 2008; 111(12): 5756 - 5757. [Full Text] [PDF]

				P. Ouillette, H. Erba, L. Kujawski, M. Kaminski, K. Shedden, and S. N. Malek Integrated Genomic Profiling of Chronic Lymphocytic Leukemia Identifies Subtypes of Deletion 13q14 Cancer Res., February 15, 2008; 68(4): 1012 - 1021. [Abstract] [Full Text] [PDF]

				G. Roos, A. Krober, P. Grabowski, D. Kienle, A. Buhler, H. Dohner, R. Rosenquist, and S. Stilgenbauer Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia Blood, February 15, 2008; 111(4): 2246 - 2252. [Abstract] [Full Text] [PDF]

				B. Stamatopoulos, N. Meuleman, B. Haibe-Kains, H. Duvillier, M. Massy, P. Martiat, D. Bron, and L. Lagneaux Quantification of ZAP70 mRNA in B Cells by Real-Time PCR Is a Powerful Prognostic Factor in Chronic Lymphocytic Leukemia Clin. Chem., October 1, 2007; 53(10): 1757 - 1766. [Abstract] [Full Text] [PDF]

				D. Kienle, T. Katzenberger, G. Ott, D. Saupe, A. Benner, H. Kohlhammer, T. F.E. Barth, S. Holler, J. Kalla, A. Rosenwald, et al. Quantitative Gene Expression Deregulation in Mantle-Cell Lymphoma: Correlation With Clinical and Biologic Factors J. Clin. Oncol., July 1, 2007; 25(19): 2770 - 2777. [Abstract] [Full Text] [PDF]

				L. D. Vallat, Y. Park, C. Li, and J. G. Gribben Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells Blood, May 1, 2007; 109(9): 3989 - 3997. [Abstract] [Full Text] [PDF]

				A. M. Buhl, J. Jurlander, F. S. Jorgensen, A. M. Ottesen, J. B. Cowland, L. M. Gjerdrum, B. V. Hansen, and H. Leffers Identification of a gene on chromosome 12q22 uniquely overexpressed in chronic lymphocytic leukemia Blood, April 1, 2006; 107(7): 2904 - 2911. [Abstract] [Full Text] [PDF]

				D. Kienle, A. Benner, A. Krober, D. Winkler, D. Mertens, A. Buhler, T. Seiler, U. Jager, P. Lichter, H. Dohner, et al. Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes Blood, March 1, 2006; 107(5): 2090 - 2093. [Abstract] [Full Text] [PDF]